GIP (Total) ELISA - Cosmo Bio Co.,Ltd.

Antibodies

>

GIP (Total) ELISA

Catalog No.: YII-YK253-EX
Size: 1KIT
Price: ¥79000
$1054
antigen/source: GIP (Total)
Application: Enzyme Linked Immunosorbent Assay
Storage: 4C
@
Immunogen: Human
Measurement Range: 3.1-200pM

Other:

 Background The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagons-like peptide-1 (GLP-1), are a group of gastrointestinal hormones that cause an increase in the amount of
insulin released from the beta cells ofthe islets of Langerhans after ingestion of food.
The intestinal peptide GIP was first isolated from porcine upper small intestine1). The sequences of
porcine2) 3), bovine4) and human GIP5) have been determined, each has 42 amino acids, and thesequences
is highly conserved. The porcine and bovine peptides differ from the human at two and three site,
respectively. Takeda et al. have isolated a human cDNA encoding the GIP precursor and confirming that
GIP belongs to the vasoactive intestinal peptide (VIP)/Glucagon/secretin family6).

GIP is a gastrointestinal peptide hormone that is released from duodenal endocrine K cells after absorption of
glucose or fat7). GIP is a potent releaser of insulin in experimental animals8) and in man 9,10) provided
that the blood glucose is above basal level. Plasma level of GIP is elevated after an oral glucose load or a
meal in normal man. This increase after a meal is below normal in newly diagnosed insulin?dependent
diabetics11).

It is now being recognized that GIP receptor is also expressed in organs and cells such as
duodenum, small intestine, pancreatic alpha-cell, adipocyte and osteoblast. These results demonstrate
GIP may have a lot of physiological effect inaddition to their glucoregulatory effects12,13,14,15).
GIP is rapidly inactivated by the enzyme dipeptidyl peptidase- 4 (DPP- 4) to GIP (3-42) with a blood
half-life of only several minutes. DPP- 4 inhibitor can prolong the half-life of GIP, that expecting
treatment of incretin effect.
The kit can be used for measurement of total GIP [both GIP (1-42) and GIP (3-42)] in human plasma
with high sensitivity. It will be a specifically useful tool for incretin research.
[Characteristics]ThisELISA kit is used for quantitative determination of human total GIP in plasma and culture medium
supernatant. The kit is characterized by its sensitive quantification and high specificity. In addition, it
has no influence by other components in samples. GIP standard is highly purified synthetic product.
< Specificity >
This ELISA kit has high specificity to human GIP(1-42) and GIP(3-42), and shows no cross reactivity to
Glucagon, GLP-1(7-37), GLP-1(7-36) NH2, GLP-1(9-36) NH2and human GLP-2.
< Assay principle >
This ELISA kit for determination of human total GIP is based on a sandwich enzyme immunoassay. To
the wells of plate coated with highly purified mouse monoclonal antibody against human GIP, standards
orsamples are added for the 1st step immunoreaction. After the 1st step incubation and plate washing,
HRP labeled antibody solution against human GIP is added as the 2nd step to form antibody - antigen -
labeled antibody complex on the surface ofthe wells. After the 2nd step incubation and rinsing out
excess labeled antibody, Finally, HRP enzyme activity is determined by 3,3f,5,5f-Tetramethylbenzidine
(TMB) and the concentration of human total GIP is calculated.



 IMAGE1



Performance Characteristics

Reference:

•  Brown,J.C., Mutt, V. and Pedersen,R.A. (1970) Further purification of a polypeptide demonstrating enterogastrone activity. J.Physiol. 209, 57-64
•  Jornvall H, Carlquist M, Kwauk S, Otte SC, McIntosh CH, Brown JC, Mutt V. (1981) Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP). FEBS Lett. 123, 205-210.
•  Moody,A.J., Damm Jorgensen, K.and Thim, L.(1981)Diabetologia 21, 306, abstr.
•  Carlquist M, Maletti M, Jornvall H, Mutt V. (1984) A novel form of gastricinhibitory polypeptide (GIP) isolated from bovine intestine using a radioreceptor assay. Fragmentation with staphylococcal protease results in GIP1-3 and GIP4-42, fragmentation with enterokinase in GIP1-16 and GIP17-42. Eur.J. Biochem. 145, 573-577
•  Moody, A. J., Thim, L. & Valverde, I. (1984) The isolation and sequencing of human gastric inhibitory peptide(GIP). FEBS Lett. 172, 142-148
•  Takeda J, Seino Y, Tanaka K, Fukumoto H, Kayano T, Takahashi H, Mitani T, Kurono M, Suzuki T, Tobe T, et al.(1987) Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proc Natl Acad Sci U S A. 84(20):7005-8.
•  Pederson, R.A. (1994) in Gut Peptides: Biochemistry and Physiology, eds, Walsh, J.H.& Dockray, G.J. (Raven, New York), pp,217-260
•  Rabinovitch, A. and Dupre, J (1974)Effect of the gastric inhibitory polypeptide present in impure pancreozymin-cholecystokinin of plasma insulin and glucagons in the rat. Endocrinology 94, 1139-1144
•  Dupre,J., Ross, S.A.,Watson, D. and Brown, J.C. (1973) Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. 37, 826-828
•  Elahi, D., Andersen, D.K., Brown, J.C.,Debas, H.T., Hershcopf,R.J.,Raizes, G.S., Tobin, J.D.and Andres, R.(1979) Pancreatic alpha-and-beta-cell response to GIP infusion in normal man. Am.J.Physiol. 237, E185-E191
•  Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ, Sestoft L.(1983) Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J Clin Endocrinol Metab. 56, 1306-12.
•  Naitoh R, Miyawaki K, Harada N, Mizunoya W, Toyoda K, Fushiki T, Yamada Y, SeinoY, Inagaki N.(2008) Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice. Biochem Biophys Res Commun. 376, 21-5.
•  Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, TsudaK, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Seino Y. (1999) Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A.96, 14843-7.
•  Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y.(2002) Inhibitionof gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 8, 738-42.
•  Tsukiyama K, Yamada Y, Yamada C, Harada N, Kawasaki Y, Ogura M, Bessho K, Li M, Amizuka N, Sato M, Udagawa N, Takahashi N, Tanaka K, Oiso Y, Seino Y. (2006) Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol. 20, 1644-51.
 
>